Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? a pilot study

Angiology

Volumn 60, Issue 5, 2009, Pages 588-595

  Gluba, Anna ^a   Banach, MacIej ^a   Rysz, Jacek ^a   Piotrowski, Grzegorz ^c   Fendler, Wojciech ^a   Pietrucha, Tadeusz ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c M Kopernik Specialist District Hospital   (Poland)

Author keywords

ENOS; Gensini score; Myocardial infarction; Polymorphisms

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY SPASM; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GENSINI SCORE; HEART INFARCTION; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGE OF ONSET; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; PHENOTYPE; PILOT PROJECTS; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 70350516785     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709335031     Document Type: Article

References (64)

1. Kowalski J., Barylski M., Banach M., Grycewicz J., Irzmanski R., Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharm. 2006 ; 48 (4). 143-147.
2. Winkelmann BR, Hager J., Kraus WE, et al. Genetics of coronary heart disease: current knowledge and research principles. Am Heart J. 2000 ; 140 (4). S11 - S26.
3. Kelm M. Significance of vascular nitric oxide synthase pathways in coronary artery disease. A multiple-level biomarker strategy. J Am Coll Cardiol. 2006 ; 48 (6). 1175-1176.
4. Rios DL, Dĝ€™Onofrio LO, Souza JK, et al. Smoking-dependent and haplotype-specific effects of endothelial nitric oxide synthase gene polymorphisms on angiographically assessed coronary artery disease in Caucasian- and African-Brazilians. Atherosclerosis. 2007 ; 193 (1). 135-141.
5. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D., Robinson J., Deanfield JE Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994 ; 24 (2). 471-476.
6. Goch A., Banach M., Mikhailidis DP, Rysz J., Goch JH Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hyper-tens. 2009 ; 31 (1). 20-30.
7. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001 ; 104 (22). 2673-2678.
8. Antoniades C., Tousoulis D., Vasiliadou C., et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction (abstract). J Am Coll Cardiol. 2005 ; 46 (6). 1101-1109.
9. Morray B., Goldenberg I., Moss AJ, et al. Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction. Am J Cardiol. 2007 ; 99 (8). 1100-1105.
10. Irokawa M., Nishinaga M., Funayama H., Shimada K. The effect of endothelium-derived relaxing factor (EDRF) on anticoagulant heparan sulfate on cultured vascular endothelial cell (EC). Circulation. 1994 ; 90 (5). I - 396.
11. Huang PL, Huang Z., Mashimo H. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995 ; 377 (6546). 239-242.
12. Schmidt HH, Walter U. NO at work. Cell. 1994 ; 78 (6). 919-925.
13. Ross R. Atherosclerosis-an inflammatory disease. Nature. 1999 ; 340 (2). 115-126.
14. Lee CR, North KE, Bray MS, et al. NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the atherosclerosis risk in communities study. Pharmacogenet Genomics. 2006 ; 16 (12). 891-899.
15. Guzik TJ, Black E., West NE, et al. Relationship between the G894T polymorphism (Glu 298Asp variant) in endothelial nitric oxide synthase and nitric oxide mediated endothelial function in human atherosclerosis. Am J Med Genetics. 2001 ; 100 (2). 130-137.
16. Al Suwaidi J., Hamasaki S., Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000 ; 101 (9). 948-954.
17. FÖrstermann U., Boissel JP, Kleinert H. Expressional control of the ĝ€constitutiveĝ€™ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 1998 ; 12 (10). 773-790.
18. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the ĝ€ĝ€Yin-Yangĝ€™ĝ€™ effect-a Chinese concept for a worldwide pandemic. Swiss Med Wkly. 2006 ; 136 (7-8). 103-113.
19. White CR, Brock TA, Chang LY, et al. Superoxide and peroxynitrite in atherosclerosis. Natl Acad Sci U S A. 1994 ; 91 (3). 1044-1048.
20. Beckman JS, Beckman TW, Chen J., Marshall PA, Freeman BA Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990 ; 87 (4). 1620-1624.
21. Rios DL, Callegari-Jacques SM, Hutz MH Endothelial nitric oxide synthase and fractalkine chemokine receptor polymorphisms on angiographically assessed coronary atherosclerosis. Clin Chim Acta. 2005 ; 362 (1-2). 138-146.
22. Alvarez R., Gonzales P., Batalla A., et al. Association between the NOS3 (-786T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide. 2001 ; 5 (4). 343-349.
23. Casas JP, Bautista LE, Humphries SE, Hingorani AD Endothelial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects. Circulation. 2004 ; 109 (11). 1359-1365.
24. Yoshimura M., Yasue H., Nakayama M. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T786C and missense Glu298Asp variants. J Investig Med. 2000 ; 48 (5). 367-374.
25. Miyamoto Y., Yoshihiko S., Kajiyama M., et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension. 1998 ; 32 (1). 3-8.
26. Gomma AH, Elrayess MA, Knight CJ, Hawe E., Fox KM, Humphries SE The endothelial nitric oxide synthase (Glu298Asp and -786T/C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J. 2002 ; 23 (24). 1955-1962.
27. Jeerooburkhan N., Jones LC, Bujac S., et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension. 2001 ; 38 (5). 1054-1061.
28. Hingorani AD, Jia H., Stevens PA, Monteith MS, Brown MJ A common variant in exon 7 of the endothelial constitutive nitric oxide synthase gene. Clin Sci. 1995 ; 88: 21P.
29. Poirier O., Mao C., Mallet C., et al. Polymorphisms of the endothelial nitric oxide synthase gene: no consistent association with myocardial infarction in ECTIM study. Eur J Clin Invest. 1999 ; 29 (4). 284-290.
30. Bonnardeaux A., Nadaud S., Charru A., Jeunemaitre X., Corvol P., Soubrier F. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation. 1995 ; 91 (1). 96-102.
31. Miyamoto Y., Saito Y., Nakayama M. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a 786T/C mutation associated with coronary spastic angina. Hum Mol Genet. 2000 ; 9 (18). 2629-2637.
32. Nakayama M., Yasue H., Yoshimura M., et al. T-786C mutation in the 5ĝ€™-flanking region of the enothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999 ; 99 (22). 2864-2870.
33. Cattaruzza M., Guzik TJ, Slodowski W., et al. Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res. 2004 ; 95 (8). 841-847.
34. Senthil D., Raveendran M., Shen YH, et al. Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. DNA Cell Biol. 2005 ; 24 (4). 218-224.
35. Tesauro M., Thompson WC, Rogliani P., Qi L., Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 2000 ; 97 (6). 2832-2835.
36. Golser R., Gorren AC, Mayer B., Schmidt K. Functional characterization of Glu298Asp mutant human endothelial nitric oxide synthase purified from a yeast expression system. Nitric Oxide. 2003 ; 8 (1). 7-14.
37. McDonald DM, Alp NJ, Channon KM Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics. 2004 ; 14 (12). 831-839.
38. Joshi MS, Mineo C., Shaul PW, Bauer JA Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J. 2007 ; 21 (11). 2655-2663.
39. Busconi L., Michel T. Endothelial nitric oxide synthase. N-Terminal myristoylation determines subcellular localization. J Biol Chem. 1993 ; 268 (12). 8410-8413.
40. Rossi GP, Cesari M., Zanchetta M., et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol. 2003 ; 41 (6). 930-937. (Pubitemid 36315532)
41. Setoguchi S., Hirooka Y., Eshima K., Shimokawa H., Takeshita A. Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J Cardiovasc Pharmacol. 2002 ; 39 (3). 363-368.
42. Derebecka N., HoÅysz M., Dankowski R., Wierzchowiecki M., Trzeciak WH Polymorphism in intron 23 of the endothelial nitric oxide synthase gene (NOS3) is not associated with hypertension. Acta Biochimica Polonica. 2008 ; 49 (1). 263-268.
43. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction The Joint European Society of Cardiology/ American College of Cardiology Committee. Eur Heart J. 2000 ; 21 (18). 1502-1503.
44. Gensini GG A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983 ; 51 (3). 606.
45. Sambrook JE, Fritsch F., Maniatis T. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor ; 1989.
46. Ye S., Dhillon S., Ke X., Collins AR, Day INM. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001 ; 29 (17). e88.
47. Barylski M., Kowalczyk E., Banach M., Ciewierz J., Pawlicki L., Kowalski J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology. 2009 ; 60 (1). 87-92.
48. Lip GYH, Ray KK, Shiu MF Coronary spasm in acute myocardial infarction. Case report. Heart. 1998 ; 80 (2). 197-199.
49. Horimoto M., Takenaka T., Igarashi K., Fujiwara M., Batra S. Coronary spasm as a cause of coronary thrombosis and myocardial infarction. Jpn Heart J. 1993 ; 34 (5). 627-631.
50. Tomonaga G. A study of angina pectoris due to coronary spasm in clinic cases. J Japan Physicians Assoc. 2006 ; 20 (3). 566-570.
51. Hingorani AD Polymorphisms in endothelial nitric oxide synthase and atherosclerosis: John French Lecture 2000. Atherosclerosis. 2001 ; 154 (3). 521-527.
52. Casas JP, Cavalleri GL, Bautista LE, Smeeth L., Humphries SE, Hingorani AD Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. 2006 ; 164 (10). 921-935.
53. Sofowora G., Dishy V., Xie HG, et al. In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics. 2001 ; 11 (9). 809-814.
54. Godfrey V., Chan SL, Cassidy A., et al. The functional consequence of the glu298asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. Cardiovasc Drug Rev. 2007 ; 25 (3). 280-288.
55. Hibi K., Ishigami T., Tamura K., Mizushima S., Nyui N., Fujita T. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension. 1998 ; 32 (3). 521-526.
56. Hingorani AD, Liang CF, Fatibene J., Lyon A., Monteith S., Parsons A. A common variant of the endothelial nitric oxide synthase (Glu298 ? Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999 ; 100 (14). 1515-1520.
57. Rossi GP, Maiolino G., Zanchetta M., et al. The T786C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol. 2006 ; 48 (6). 1166-1174.
58. Nakayama M., Yasue H., Yoshimura M., et al. T-786C mutation in the 5ĝ€™-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000 ; 86 (6). 628-634.
59. Yoon Y., Song J., Hong SH, Kim JQ Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem. 2000 ; 46 (10). 1626-1630.
60. Heusch P., Skyschally A., Leineweber K., Haude M., Erbel R., Heusch G. The interaction of coronary microembolization and ischemic preconditioning: a third window of cardioprotection through TNF-alpha. Arch Med Sci. 2007 ; 3 (2). 83-92.
61. Okonski P., Banach M., Rysz J., et al. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Ann Transplant. 2006 ; 11 (1). 26-32.
62. Kolovou G., Daskalova D., Mikhailidis DP Apolipoprotein E polymorphism and atherosclerosis. Angiology. 2003 ; 54 (1). 59-71.
63. Piestrzeniewicz K., Åuczak K., Maciejewski M., Goch JH Impact of obesity and adipokines on cardiac structure and function in men with first myocardial infarction. Arch Med Sci. 2008 ; 4 (2). 152-160.
64. Banach M., Rysz J., Goch A., Mikhailidis DP, Rosano GM The role of trimetazidine after acute myocardial infarction. Curr Vascul Pharamacol. 2008 ; 6 (4). 282-291.